

**LYTGOBI  
(futibatinib)**

**Pre - PA Allowance**

None

---

**Prior-Approval Requirements**

**Age** 18 years of age or older

**Diagnosis**

Patient must have the following:

1. Unresectable locally advanced or metastatic cholangiocarcinoma
  - a. Fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement
  - b. Patient has had at least one prior therapy

**AND ALL** of the following:

- a. Baseline ophthalmological examination has been done and patient will be monitored for retinal pigment epithelial detachment (RPED)
- b. Prescriber agrees to monitor for hyperphosphatemia and agrees to initiate a low phosphate diet or phosphate lowering therapy, as clinically indicated
- c. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Lytgobi and for 1 week after the last dose
- d. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Lytgobi and for 1 week after the last dose

**Prior - Approval Limits**

**Quantity** 420 tablets per 84 days

**Duration** 12 months

---

**Prior – Approval *Renewal* Requirements**

**Age** 18 years of age or older

**Diagnosis**



**BlueCross  
BlueShield**

Federal Employee Program.

## **LYTGOBI (futibatinib)**

Patient must have the following:

1. Unresectable locally advanced or metastatic cholangiocarcinoma

**AND ALL** of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Patient will be monitored for retinal pigment epithelial detachment (RPED)
- c. Prescriber agrees to monitor for hyperphosphatemia and agrees to initiate a low phosphate diet or phosphate lowering therapy, as clinically indicated
- d. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Lytgobi and for 1 week after the last dose
- e. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Lytgobi and for 1 week after the last dose

## **Prior - Approval *Renewal* Limits**

Same as above